Daptomycin Accord Healthcare

What Is Daptomycin Accord Healthcare and What Is It Used For?

Quick Answer: Daptomycin Accord Healthcare is a cyclic lipopeptide antibiotic given intravenously to treat serious infections caused by Gram-positive bacteria, including complicated skin infections, bloodstream infections (S. aureus bacteraemia), and right-sided infective endocarditis.

Daptomycin is a naturally derived cyclic lipopeptide antibiotic originally isolated from the soil organism Streptomyces roseosporus. It represents a distinct class of antibacterials with a unique mechanism of action that differs fundamentally from other antibiotic classes. Daptomycin Accord Healthcare is a generic formulation manufactured by Accord Healthcare, containing 350 mg of daptomycin as a powder that must be reconstituted before intravenous administration.

The European Medicines Agency (EMA) has approved daptomycin for the following indications in adults: complicated skin and soft tissue infections (cSSTI), Staphylococcus aureus bacteraemia (SAB), and right-sided infective endocarditis (RIE) caused by S. aureus. In paediatric patients aged 1 to 17 years, it is approved for cSSTI. The Infectious Diseases Society of America (IDSA) guidelines recommend daptomycin as a first-line alternative to vancomycin for MRSA infections, particularly when vancomycin minimum inhibitory concentrations (MICs) are elevated.

Daptomycin works by binding to bacterial cell membranes in a calcium-dependent process. Once bound, it inserts its lipophilic tail into the membrane, causing rapid depolarisation. This loss of membrane potential leads to the cessation of DNA, RNA, and protein synthesis, ultimately resulting in bacterial cell death without cell lysis. This bactericidal mechanism is concentration-dependent, meaning higher drug concentrations produce more rapid killing, and daptomycin exhibits a prolonged post-antibiotic effect lasting several hours.

The spectrum of activity covers most clinically relevant Gram-positive organisms, including methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci, Enterococcus faecalis (including vancomycin-resistant strains), Enterococcus faecium (including vancomycin-resistant strains), and various streptococcal species. Daptomycin is not active against Gram-negative organisms because it cannot penetrate the outer membrane of Gram-negative bacteria.

What Should You Know Before Taking Daptomycin Accord Healthcare?

Quick Answer: Before starting daptomycin, your doctor should check your kidney function, current medications (especially statins), and baseline CPK levels. Daptomycin should be used with caution in patients with renal impairment and is not recommended during pregnancy unless clearly necessary.

Contraindications

Daptomycin is contraindicated in patients with known hypersensitivity to daptomycin or any of the excipients in the formulation. While true allergic reactions to daptomycin are uncommon, anaphylaxis and hypersensitivity reactions including angioedema, drug rash with eosinophilia and systemic symptoms (DRESS), and pruritus have been reported during post-marketing surveillance. Patients with a history of severe allergic reactions to other lipopeptide compounds should exercise caution.

There are no absolute medical contraindications beyond hypersensitivity, but several clinical situations require careful consideration. Patients with pre-existing muscle disease, those currently receiving or who have recently taken HMG-CoA reductase inhibitors (statins), and patients with unexplained elevations in creatine phosphokinase (CPK) require close monitoring and risk-benefit assessment before initiating daptomycin therapy.

Warnings and Precautions

Muscle toxicity and CPK monitoring: Daptomycin can cause elevations in creatine phosphokinase (CPK), which may be associated with muscle pain, weakness, or in rare cases, rhabdomyolysis. CPK levels should be measured at baseline and then monitored at least weekly during treatment. Daptomycin should be discontinued if CPK levels rise above five times the upper limit of normal (5x ULN) in patients with symptoms, or if CPK rises above 10x ULN regardless of symptoms. Patients should be advised to report unexplained muscle pain, tenderness, or weakness during treatment.

Eosinophilic pneumonia: Rare cases of eosinophilic pneumonia have been reported in patients receiving daptomycin. This potentially serious condition typically presents with fever, dyspnoea, diffuse pulmonary infiltrates, and peripheral eosinophilia. Onset has been reported from 2 days to 6 weeks after starting therapy. Patients developing these symptoms should have daptomycin discontinued immediately and should receive appropriate treatment, which may include systemic corticosteroids.

Renal impairment: Daptomycin is primarily eliminated by renal excretion. In patients with severe renal impairment (creatinine clearance <30 mL/min), including those receiving haemodialysis or continuous ambulatory peritoneal dialysis (CAPD), the dosing interval should be extended to once every 48 hours. More frequent CPK monitoring is recommended in these patients due to the potential for drug accumulation.

Peripheral neuropathy: Cases of peripheral and cranial neuropathy have been reported during daptomycin treatment. Patients should be monitored for signs and symptoms of neuropathy, and daptomycin should be discontinued if neuropathy develops.

Clostridioides difficile-associated diarrhoea (CDAD): As with all antibiotics, daptomycin use may result in overgrowth of non-susceptible organisms, including C. difficile. Patients developing diarrhoea during or after treatment should be evaluated for CDAD. Mild cases may resolve following discontinuation of daptomycin, while severe cases may require specific treatment with oral vancomycin or fidaxomicin.

Pregnancy and Breastfeeding

There are no adequate and well-controlled studies of daptomycin in pregnant women. Animal reproduction studies in rats and rabbits have not demonstrated teratogenic effects, but embryo-foetal toxicity (decreased foetal weight and delayed ossification) was observed in rats at doses approximately equivalent to human therapeutic doses. Daptomycin should only be used during pregnancy if the potential benefit justifies the potential risk to the foetus, and only when no suitable alternative therapy is available.

It is not known whether daptomycin is excreted in human breast milk. A decision must be made whether to discontinue breastfeeding or to discontinue daptomycin therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. The molecular weight (approximately 1,620 Da) suggests limited transfer into breast milk, but clinical data are insufficient to confirm safety during lactation.

How Does Daptomycin Accord Healthcare Interact with Other Drugs?

Quick Answer: The most clinically significant interaction is with statins (HMG-CoA reductase inhibitors), which should ideally be suspended during daptomycin therapy due to additive risk of muscle toxicity. Daptomycin does not interact with cytochrome P450 enzymes and has limited pharmacokinetic interactions.

Daptomycin does not inhibit or induce the cytochrome P450 (CYP450) enzyme system, which significantly limits its potential for pharmacokinetic drug interactions. The drug is neither a substrate for nor an inhibitor of P-glycoprotein (P-gp). However, several clinically relevant interactions have been identified, primarily related to pharmacodynamic effects rather than altered drug metabolism.

Major Interactions

HMG-CoA reductase inhibitors (statins): This is the most important drug interaction for daptomycin. Both daptomycin and statins can independently cause skeletal muscle toxicity (rhabdomyolysis). When used concomitantly, the risk may be additive. International guidelines, including the EMA Summary of Product Characteristics and FDA prescribing information, recommend temporarily suspending statin therapy during daptomycin treatment. If co-administration is considered necessary, CPK levels should be monitored more frequently than once weekly, ideally every 2-3 days.

Other drugs associated with myopathy: Similarly, concomitant use of daptomycin with other agents known to cause myopathy (such as fibrates, ciclosporin, or colchicine) may increase the risk of muscle damage. These combinations should be used with caution and with enhanced CPK monitoring.

Minor Interactions

Tobramycin: In vitro studies have shown synergistic activity between daptomycin and aminoglycosides, including tobramycin and gentamicin. While pharmacokinetic studies demonstrate no significant alteration of either drug's plasma concentrations, the clinical significance of this synergy may be relevant when treating difficult infections. No dose adjustment is required for either drug.

Warfarin: Co-administration studies have shown no clinically significant interaction between daptomycin and warfarin. However, as with initiation of any antibiotic in patients on warfarin, closer monitoring of INR is prudent during the first few days of co-administration due to potential alterations in vitamin K-producing gut flora.

Probenecid: Probenecid does not significantly alter the pharmacokinetics of daptomycin. No dose adjustment is required.

What Is the Correct Dosage of Daptomycin Accord Healthcare?

Quick Answer: For adults, the standard dose is 4 mg/kg once daily for skin infections and 6 mg/kg once daily for bacteraemia and endocarditis. The drug is given as a 30-minute IV infusion or a 2-minute IV injection. Dose adjustment is needed for severe renal impairment.

Daptomycin dosing is weight-based and indication-specific. The powder must be reconstituted with 7 mL of 0.9% sodium chloride (normal saline) for injection to produce a concentration of 50 mg/mL. The reconstituted solution can then be administered directly as a slow intravenous injection over 2 minutes, or diluted further in 50 mL of 0.9% sodium chloride and administered as a 30-minute intravenous infusion. Daptomycin must NOT be mixed with or administered through the same intravenous line as glucose-containing solutions, as glucose causes daptomycin to be incompatible.

Adults

The duration of treatment should be guided by clinical response, the site and severity of infection, and microbiological findings. For uncomplicated bacteraemia with rapid clearance, 2 weeks may suffice, while endocarditis typically requires 4-6 weeks. Treatment should not be discontinued prematurely even if clinical improvement is noted, as this increases the risk of treatment failure and the development of resistance.

Children

Daptomycin is approved for paediatric patients aged 1 to 17 years for the treatment of complicated skin and soft tissue infections. Paediatric dosing is higher on a per-kilogram basis than adult dosing because children have higher daptomycin clearance relative to body weight. The recommended dosing regimen varies by age group:

Daptomycin is not recommended for use in neonates (less than 1 year of age) due to the potential for effects on the developing muscular, neuromuscular, and/or nervous systems (either peripheral or central). Animal studies in neonatal dogs demonstrated effects on skeletal and neuromuscular systems at clinically relevant doses.

Elderly Patients

No dose adjustment is required based on age alone. However, elderly patients are more likely to have decreased renal function, and renal function should be assessed before and during treatment. If creatinine clearance is below 30 mL/min, the dosing interval should be extended to every 48 hours. Elderly patients should also be monitored more carefully for signs and symptoms of muscle toxicity.

Missed Dose

If a dose of daptomycin is missed, it should be administered as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Doses should not be doubled to make up for a missed dose. Healthcare providers should document any missed doses and assess whether the treatment course needs to be extended to compensate for the missed therapy.

Overdose

In the event of overdose, supportive care is recommended. Daptomycin is slowly cleared by haemodialysis (approximately 15% removed over 4 hours) and by peritoneal dialysis (approximately 11% removed over 48 hours). High-flux dialysis membranes may improve clearance somewhat. There is no specific antidote for daptomycin overdose. Cases of overdose reported in clinical trials and post-marketing surveillance have been managed with supportive measures including monitoring of CPK levels, renal function, and musculoskeletal symptoms.

What Are the Side Effects of Daptomycin Accord Healthcare?

Quick Answer: The most common side effects include injection site reactions, fungal infections (candidiasis), headache, nausea, diarrhoea, and elevations in CPK. The most serious side effects are CPK elevation (potential rhabdomyolysis), eosinophilic pneumonia, and peripheral neuropathy.

Like all medicines, daptomycin can cause side effects, although not everyone experiences them. The side effects observed in clinical trials and post-marketing surveillance are classified below by frequency. It is essential to inform your healthcare provider immediately if you experience muscle pain, weakness, or tenderness, as these may indicate serious muscle toxicity. Similarly, any new respiratory symptoms such as cough, fever, or shortness of breath should be reported promptly, as they could indicate eosinophilic pneumonia.

Long-term safety data from clinical studies have demonstrated that the majority of side effects resolve upon discontinuation of daptomycin. CPK elevations typically normalise within 7-10 days of stopping treatment. Eosinophilic pneumonia, although rare, has been reported from 2 days to 6 weeks after treatment initiation and generally responds well to discontinuation of daptomycin with or without corticosteroid therapy.

In clinical trials involving over 2,000 patients, the overall rate of treatment-emergent adverse events was comparable to comparator agents. The discontinuation rate due to adverse events was approximately 2.8% in adult patients with cSSTI and 8.4% in patients with S. aureus bacteraemia/endocarditis, reflecting the longer duration and greater severity of illness in the latter group.

How Should You Store Daptomycin Accord Healthcare?

Quick Answer: Store unopened vials at 2-8°C (in a refrigerator). The reconstituted solution is stable for up to 12 hours at room temperature or up to 24 hours when refrigerated. Do not freeze.

Daptomycin Accord Healthcare powder for injection/infusion should be stored in the original packaging to protect from light. Unopened vials should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze the product. The shelf life of the unopened product, when stored correctly, is typically 3 years from the date of manufacture. Always check the expiry date printed on the vial and outer carton before use.

Once reconstituted with 0.9% sodium chloride for injection, the solution should be used promptly. Chemical and physical in-use stability has been demonstrated for up to 12 hours at 25°C (room temperature) and for up to 24 hours at 2-8°C (refrigerated). If diluted in a 50 mL infusion bag of 0.9% sodium chloride, the combined stability (reconstitution plus dilution) must not exceed these timeframes. From a microbiological point of view, the product should be used immediately after reconstitution. If not used immediately, the user is responsible for in-use storage times and conditions.

Reconstituted daptomycin solutions should be inspected visually for particulate matter and discolouration before administration. The solution should be clear and pale yellow to light brown. Do not use if the solution is cloudy, discoloured, or contains visible particles. Any unused product or waste material should be disposed of in accordance with local requirements for pharmaceutical waste.

What Does Daptomycin Accord Healthcare Contain?

Quick Answer: Each vial contains 350 mg of daptomycin as the active substance. The only other ingredient is sodium hydroxide, used to adjust the pH. After reconstitution, each mL contains 50 mg of daptomycin.

Daptomycin Accord Healthcare is presented as a sterile, preservative-free, lyophilised (freeze-dried) powder for reconstitution. The formulation is intentionally simple, containing only the active substance and a minimal excipient for pH adjustment.

Active substance: Each vial contains 350 mg of daptomycin. After reconstitution with 7 mL of 0.9% sodium chloride for injection, the resulting solution has a concentration of approximately 50 mg/mL. Daptomycin is a cyclic lipopeptide with a molecular weight of approximately 1,620.67 Daltons, derived from the fermentation of Streptomyces roseosporus.

Other ingredient: Sodium hydroxide (for pH adjustment). The reconstituted solution has a pH of approximately 4.7.

Sodium content: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, meaning it is essentially sodium-free. This is relevant for patients on sodium-restricted diets, such as those with heart failure or renal impairment.

Daptomycin Accord Healthcare is supplied in clear glass (Type I) vials with a rubber stopper and aluminium seal with a flip-off cap. Each vial is for single use only. The powder appears as a pale yellow to light brown lyophilised cake or powder. Packs are available containing 1 or 10 vials, although not all pack sizes may be marketed in every country.